Edwards Lifesciences (EW) Receivables - Net (2009 - 2026)

Edwards Lifesciences has reported Receivables - Net for 18 years, with the latest figure at $770.4 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 10.53% year-over-year to $770.4 million in Q2 2026; TTM through Jun 2026 was $770.4 million, a 10.53% increase from a year earlier, with the FY2025 full-year figure at $659.6 million, up 8.29% from the prior year.
• Receivables - Net was $770.4 million for Q2 2026 at Edwards Lifesciences, down from $775.7 million in the prior quarter.
• The five-year high for Receivables - Net was $817.6 million in Q1 2024, with the low at $28.8 million in Q4 2024.
• Average Receivables - Net over 5 years is $673.5 million, with a median of $706.5 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net slumped 96.27% in 2024, then jumped 2190.28% in 2025.
• Over 5 years, Receivables - Net stood at $643.0 million in 2022, then grew by 19.98% to $771.5 million in 2023, then plunged by 96.27% to $28.8 million in 2024, then surged by 2190.28% to $659.6 million in 2025, then rose by 16.8% to $770.4 million in 2026.
• The last three Receivables - Net figures came in at $770.4 million (Q2 2026), $775.7 million (Q1 2026), and $659.6 million (Q4 2025), per Business Quant data.